Renaissance Technologies LLC Has $3.44 Million Stock Holdings in Amneal Pharmaceuticals, Inc. $AMRX

Renaissance Technologies LLC raised its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 1,586.8% during the 1st quarter, HoldingsChannel reports. The fund owned 276,637 shares of the company’s stock after buying an additional 260,237 shares during the quarter. Renaissance Technologies LLC’s holdings in Amneal Pharmaceuticals were worth $3,439,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in AMRX. Artemis Investment Management LLP acquired a new position in Amneal Pharmaceuticals during the fourth quarter worth $1,574,000. Louisiana State Employees Retirement System acquired a new position in shares of Amneal Pharmaceuticals during the 1st quarter worth about $936,000. Tudor Investment Corp ET AL acquired a new position in shares of Amneal Pharmaceuticals during the 3rd quarter worth about $921,000. HighTower Advisors LLC bought a new position in shares of Amneal Pharmaceuticals in the 4th quarter valued at about $1,121,000. Finally, Quartz Partners LLC bought a new position in shares of Amneal Pharmaceuticals in the 1st quarter valued at about $5,559,000. 31.82% of the stock is owned by institutional investors.

Amneal Pharmaceuticals Trading Up 0.4%

Amneal Pharmaceuticals stock opened at $18.14 on Friday. Amneal Pharmaceuticals, Inc. has a 52 week low of $8.21 and a 52 week high of $19.26. The company has a debt-to-equity ratio of 77.65, a quick ratio of 1.44 and a current ratio of 2.20. The stock has a market capitalization of $5.79 billion, a P/E ratio of 37.02 and a beta of 1.27. The stock has a 50-day simple moving average of $16.79 and a 200 day simple moving average of $14.44.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.27 earnings per share for the quarter. The firm had revenue of $722.52 million for the quarter. Amneal Pharmaceuticals had a negative return on equity of 584.46% and a net margin of 5.05%. Analysts expect that Amneal Pharmaceuticals, Inc. will post 0.94 earnings per share for the current year.

Insider Activity at Amneal Pharmaceuticals

In other news, Director Deborah M. Autor sold 34,819 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $12.94, for a total transaction of $450,557.86. Following the completion of the transaction, the director directly owned 93,660 shares in the company, valued at approximately $1,211,960.40. The trade was a 27.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 17.30% of the company’s stock.

Wall Street Analysts Forecast Growth

AMRX has been the topic of several analyst reports. The Goldman Sachs Group reiterated a “buy” rating and set a $21.00 target price on shares of Amneal Pharmaceuticals in a report on Friday, July 31st. UBS Group boosted their price target on Amneal Pharmaceuticals from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Barclays upped their price objective on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 20th. Wall Street Zen raised shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, July 12th. Finally, Weiss Ratings upgraded shares of Amneal Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, July 29th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $17.67.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.